1. Home
  2. KTTA vs CINGW Comparison

KTTA vs CINGW Comparison

Compare KTTA & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KTTA
  • CINGW
  • Stock Information
  • Founded
  • KTTA 2020
  • CINGW N/A
  • Country
  • KTTA United States
  • CINGW United States
  • Employees
  • KTTA N/A
  • CINGW 13
  • Industry
  • KTTA Biotechnology: Pharmaceutical Preparations
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • KTTA Health Care
  • CINGW Health Care
  • Exchange
  • KTTA Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • KTTA N/A
  • CINGW N/A
  • IPO Year
  • KTTA 2021
  • CINGW 2021
  • Fundamental
  • Price
  • KTTA $1.38
  • CINGW $0.04
  • Analyst Decision
  • KTTA
  • CINGW
  • Analyst Count
  • KTTA 0
  • CINGW 0
  • Target Price
  • KTTA N/A
  • CINGW N/A
  • AVG Volume (30 Days)
  • KTTA 5.3M
  • CINGW N/A
  • Earning Date
  • KTTA 05-13-2025
  • CINGW N/A
  • Dividend Yield
  • KTTA N/A
  • CINGW N/A
  • EPS Growth
  • KTTA N/A
  • CINGW N/A
  • EPS
  • KTTA N/A
  • CINGW N/A
  • Revenue
  • KTTA N/A
  • CINGW N/A
  • Revenue This Year
  • KTTA N/A
  • CINGW N/A
  • Revenue Next Year
  • KTTA N/A
  • CINGW N/A
  • P/E Ratio
  • KTTA N/A
  • CINGW N/A
  • Revenue Growth
  • KTTA N/A
  • CINGW N/A
  • 52 Week Low
  • KTTA $0.92
  • CINGW N/A
  • 52 Week High
  • KTTA $7.69
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • KTTA 52.78
  • CINGW N/A
  • Support Level
  • KTTA $1.13
  • CINGW N/A
  • Resistance Level
  • KTTA $1.53
  • CINGW N/A
  • Average True Range (ATR)
  • KTTA 0.23
  • CINGW 0.00
  • MACD
  • KTTA 0.02
  • CINGW 0.00
  • Stochastic Oscillator
  • KTTA 26.15
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: